Bill Gates: By the End of This Year People’s Chances of Dying from the Epidemic are Expected to be “Substantially” Reduced

Drugs and tools for the treatment of new coronary pneumonia (COVID-19, also known as Wuhan pneumonia) are developing rapidly. Microsoft Corp. founder Bill Gates believes that by the end of this year, people’s chances of death from the disease are expected to be “substantially” Reduced.

CNBC reported that in an interview on the 28th, Gates pointed out that Gilead (or Gilead Sciences, Inc.) antiviral drug “remdesivir” (remdesivir) is one of the main COVID-19 therapies . Gilead previously pointed out that analysis shows that if compared with the standard course of treatment, Remdesivir can reduce the death rate of severely ill infected patients by 62%.

Gates said that scientists are currently studying two other antiviral oral drugs. He said, “Monoclonal antibodies should be the most promising treatment. Regeneron, Eli Lilly and AstraZeneca are all conducting very good research.”

However, he said that although these therapies can significantly help the severely ill infected patients, they cannot “return our lives to normal.” “As long as they can really stop the spread of the virus, no one has been hospitalized due to the infection for a long time. Before, doubts will linger.”

Pfizer (Pfizer Ltd.) and German pharmaceutical company BioNTech SE have finalized a new coronary pneumonia vaccine agreement with the US government. The US government agreed to pay Pfizer and BioNTech a total of US$1.95 billion to produce 100 million doses of the new coronary pneumonia vaccine, but the premise must be to prove that the vaccine is safe and effective. The U.S. Department of Health and Human Services (HHS) stated that the U.S. government can purchase an additional 500 million doses of vaccine based on the agreement between the two parties.

Pfizer and BioNTech also announced on July 27 that late-stage human clinical trials have begun. The candidate vaccine jointly developed by it has had preliminary positive results. After the second dose, the vaccine successfully produced a high level of immune response and neutralizing antibodies in the body. Experiments have confirmed that the vaccine is safe and effective.

Moderna Inc., an mRNA therapy and vaccine biotechnology industry, also received US$472 million from the US government on the 27th to assist the company in developing a new coronary pneumonia vaccine.